Lentigo maligna: a comprehensive review on diagnosis and treatment

Ital J Dermatol Venerol. 2024 Aug;159(4):390-411. doi: 10.23736/S2784-8671.24.07837-X.

Abstract

Lentigo maligna (LM), a form of melanoma in situ, and LM melanoma (LMM), its invasive counterpart, exhibit distinctive epidemiology, risk factors, and clinical features compared to other melanoma subtypes. Notably, LM occurs on chronically sun-damaged skin presenting as a slow-growing, ill-defined patch which makes it difficult to diagnose and to treat. Additionally, while LM generally presents a favourable prognosis, it can also lead to dermal invasion and behave similarly to other melanomas with the same Breslow thickness. Hence, surgery continues to be the cornerstone treatment. Wide excisions are often necessary, but challenges arise when these lesions manifest in cosmetically sensitive regions, limiting the feasibility and desirability of large excisions. Specialized approaches, including margin-controlled surgery and image-guided treatment with reflectance confocal microscopy, have been developed to address these issues. Other non-surgical treatments such as cryosurgery, imiquimod, radiotherapy, or photodynamic therapy, may also be used but commonly present with recurrent/persistent disease. Herein we comprehensively review the existing literature on the management of LM/LMM, and discus the potential new advances on managing this challenging skin cancer.

Publication types

  • Review

MeSH terms

  • Humans
  • Hutchinson's Melanotic Freckle* / diagnosis
  • Hutchinson's Melanotic Freckle* / therapy
  • Imiquimod / therapeutic use
  • Photochemotherapy
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / pathology
  • Skin Neoplasms* / therapy

Substances

  • Imiquimod